BeyondSpring Reports 2025 Year-End Financial Results

Core Insights - BeyondSpring Inc. reported significant clinical and operational progress in 2025, particularly with its lead program Plinabulin, and highlighted strategic developments related to its equity interest in SEED Therapeutics [2][3] Clinical and Operational Progress - The company advanced its Phase 3 Plinabulin program for non-small cell lung cancer (NSCLC) and generated meaningful clinical data [3] - SEED Therapeutics initiated its first clinical trial following IND clearance in both the U.S. and China, marking a critical milestone [3] - Plinabulin demonstrated a statistically significant overall survival benefit in the DUBLIN-3 study compared to docetaxel alone, with a median overall survival improvement of 2.5 months [6][11] - The DUBLIN-4 confirmatory trial is planned to further evaluate Plinabulin in a biomarker-selected patient population [8][9] Financial Developments - BeyondSpring completed a $30 million Series A-3 financing and appointed Dr. Bill Desmarais as Chief Financial Officer and Chief Business Officer [19] - The company reported a net loss of $8.7 million for 2025, slightly improved from a net loss of $8.9 million in 2024 [19][24] - Cash, cash equivalents, and short-term investments totaled $12.6 million as of December 31, 2025 [19] Future Outlook - BeyondSpring is focused on advancing the DUBLIN-4 trial for Plinabulin and supporting SEED's Phase 1a clinical program for ST-01156 in solid tumors [4] - The company aims to create long-term value for shareholders through its strategic initiatives and clinical advancements [4]